Overview

The Study of Chinese Medicine for the Treatment of Chronic Atrophic Gastritis

Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate efficacy of Chinese medicine treatment for chronic atrophic gastritis. It is a multi-center, randomized, placebo-controlled trial.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Wangjing Hospital, China Academy of Chinese Medical Sciences
Collaborators:
Beijing Hospital of Traditional Chinese Medicine
Beijing University of Chinese Medicine
First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Gansu Provincial Hospital
Guangdong Provincial Hospital of Traditional Chinese Medicine
Hebei Hospital of Traditional Chinese Medicine
Liaoning Hospital of TCM
Shaanxi Hospital of Traditional Chinese Medicine
Shanghai University of Traditional Chinese Medicine
Shanxi Hospital of Traditional Chinese Medicine
Shanxi Province hospital Research Institute of Traditional Chinese Medicine
ShenZhen AiUYi Health Management Co.,Ltd
The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
Tianjin Nankai Hospital
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Yueyang Hospital of Integrated Traditional Chinese Medicine and Western Medicine
Treatments:
Hydrotalcite
Criteria
Inclusion criteria

1. Patients diagnosed with chronic atrophic gastritis.

2. Patients whose pathological diagnosis was atrophy (reduction glands) of mild/moderate
grade,with or without intestinal metaplasia, with or without mild/moderate dysplasia.

3. Aged between 40 to 65 years old, male or female.

4. Patients who agree to participate in the clinical study through informed consent.

5. Local residents ensuring regular treatment and follow-up.

6. Not taking aspirin, warfarin and other anticoagulants and those without coagulation
disorders.

Exclusion criteria

1. Autoimmune gastritis.

2. The combined gastric and duodenal ulcers, upper gastrointestinal bleeding.

3. Dysplasia of severe degree,or suspicious of gastric malignancy.

4. Serious comorbidities of heart, lung, liver, kidney or blood system (such as cardiac
function above grade II, alanine aminotransferase (ALT) and/or aspartate
aminotransferase (AST) greater than 1.5 times the upper limit of normal, creatinine
(Cr) greater than the upper limit of normal and so on) or having a life-threatening
illness .

5. Psychiatric disorders or a history of alcohol or drug abuse.

6. Pregnant or lactating women.

7. Allergic to the trial drug.

8. Patients judged inappropriate to participate in the trial by investigators.

9. Patients enrolled in another clinical trial last two months.